Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

Table 2 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients with low (<8 %) and high (≥8 %) baseline HbA1c levels

Outcome	Effect estimate	95 % Confidence limits		p value	Effect estimate	95 % Confidence limits		p value
		Lower	Upper			Lower	Upper
		Low (<8 %) baseline HbA1c				High (≥8 %) baseline HbA1c
Change in HbA1c (%)	−0.80	−1.18	−0.43	<0.0001	−1.19	−1.46	−0.92	<0.0001
Change in weight (kg)	−0.62	−1.72	0.49	0.28	−0.17	−0.68	0.34	0.52
Change in FPG (mg/dL)	−12.5	−30.9	5.8	0.18	−14.7	−25.9	−3.6	0.0097
Change in PPG: meal test (mg/dL)	−132.0	−171.7	−92.4	<0.0001	−162.0	−185.9	−138.1	<0.0001

	Odds ratio	95 % Confidence limits		p value	Odds ratio	95 % Confidence limits		p value
		Lower	Upper			Lower	Upper
		Low (<8 %) baseline HbA1c				High (≥8 %) baseline HbA1c
Symptomatic hypoglycemia	2.9	0.8	10.0	0.10	2.9	1.2	7.1	0.0229
Severe hypoglycemia	0.0	0.0	0.0	–	0.0	0.0	0.0	–
Endpoint HbA1c <7 %	25.5	5.2	124.6	<0.0001	15.8	2.9	85.6	0.0014
Endpoint HbA1c <7 % and no weight gain	15.8	3.3	75.8	0.0005	10.0	1.8	55.9	0.0091
Endpoint HbA1c <7 % and no symptomatic hypoglycemia	11.8	2.0	68.7	0.0060	11.1	2.0	61.8	0.0059
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia	8.9	1.5	52.2	0.0154	6.4	1.1	38.6	0.0430